Patents by Inventor Alexander Fred Markham

Alexander Fred Markham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nanomaterials
    Patent number: 12017284
    Abstract: The present application relates to a method for the production of a noble metal nanomaterial comprising: (A) adding an aqueous solution of a source of noble metal ions and a reducing agent to an aqueous solution of an organic compound to form a reaction mixture, wherein the organic compound is capable of undergoing 2D planar stacking in aqueous solution; and (B) separating the noble metal nanomaterial from the reaction mixture. The present application also relates to a noble metal nanomaterial manufactured according to said method.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: June 25, 2024
    Assignee: University of Leeds
    Inventors: Stephen Derek Evans, Sunjie Ye, Alexander Fred Markham, Patricia Louise Coletta
  • NANOMATERIALS
    Publication number: 20210402472
    Abstract: The present application relates to a method for the production of a noble metal nanomaterial comprising: (A) adding an aqueous solution of a source of noble metal ions and a reducing agent to an aqueous solution of an organic compound to form a reaction mixture, wherein the organic compound is capable of undergoing 2D planar stacking in aqueous solution; and (B) separating the noble metal nanomaterial from the reaction mixture. The present application also relates to a noble metal nanomaterial manufactured according to said method.
    Type: Application
    Filed: November 19, 2019
    Publication date: December 30, 2021
    Applicant: UNIVERSITY OF LEEDS
    Inventors: Stephen Derek EVANS, Sunjie YE, Alexander Fred MARKHAM, Patricia Louise COLETTA
  • Latency-associated regulatory region from (HVS)
    Patent number: 7227012
    Abstract: A nucleic acid encoding a promoter and comprising a nucleic acid sequence of SEQ ID NO:1, fragments and/or variants thereof, for use in gene therapy derived from the Herpesvirus saimiri (HVS) ORF73 (ECLFI) gene. The invention also includes a gene therapy system and an HVS vector system including the promoter.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: June 5, 2007
    Assignee: The University of Leeds
    Inventors: Alexander Fred Markham, Adrian Whitehouse, Kersten Hall, Aida Meredith, legal representative, David Meredith, deceased
  • EHV-1 vectors
    Patent number: 6706515
    Abstract: The invention relates to manipulation of equine herpes virus for use in gene therapy and in particular to modifications of the virus so that it can carry heterologous material and furthermore, preferably, be replication deficient so that the virus cannot replicate in the target tissue.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: March 16, 2004
    Inventors: Alexander Fred Markham, David Mark Meredith
  • HIV vaccine
    Patent number: 6692955
    Abstract: A herpesvirus saimiri (HVS) vector which has inserted therein at least a part of a gene encoding an envelope protein of HIV for use in delivering said protein to a specific cell population such as T cell lymphocytes and/or macrophages. The invention also provides a vaccine comprising the recombinant vector.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: February 17, 2004
    Assignee: University of Leeds
    Inventors: David Mark Meredith, Alexander Fred Markham
  • Treatment of cancer and neurological diseases
    Publication number: 20030180750
    Abstract: The present invention relates to a nucleic acid molecule and the protein encoded thereby absence of which is associated with oral and other cancers and lack of neurogenesis. The invention also provides antibodies and the use of these products as therapeutic and/or diagnostic agents in gene therapy and/or tissue repair.
    Type: Application
    Filed: May 8, 2003
    Publication date: September 25, 2003
    Inventors: Alexander Fred Markham, Andrew Peter Jackson, Christopher Geoffrey Woods
  • Arrestable therapeutic viral agent
    Publication number: 20030017173
    Abstract: The invention relates to the use of anti-herpetic sensitive viruses in the treatment of diseases and particularly cancer. More specifically, the invention concerns the genetic manipulation of viruses that are susceptible to anti-herpetic agents so as to enhance their sensitivity to said agents and/or reduce their pathogenicity.
    Type: Application
    Filed: September 13, 2002
    Publication date: January 23, 2003
    Inventors: Alexander Fred Markham, David Mark Meredith
  • EHV-1 vectors
    Publication number: 20020090716
    Abstract: The invention relates to manipulation of equine herpes virus for use in gene therapy and in particular to modifications of the virus so that it can carry heterologous material and furthermore, preferably, be replication deficient so that the virus cannot replicate in the target tissue.
    Type: Application
    Filed: March 18, 2002
    Publication date: July 11, 2002
    Inventors: Alexander Fred Markham, David Mark Meredith
  • Diagnosis for mutant APC by immunoassay
    Patent number: 6413727
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 2, 2002
    Assignees: The Johns Hopkins University, University of Utah, Japanese Foundation for Cancer Research Cancer Institute, Zeneca Limited
    Inventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
  • EHV-1 vectors
    Patent number: 6387685
    Abstract: The invention relates to manipulation of equine herpes virus for use in gene therapy and in particular to modifications of the virus so that it can carry heterologous material and furthermore, preferably, be replication deficient so that the virus cannot replicate in the target tissue.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: May 14, 2002
    Assignee: The University of Leeds
    Inventors: Alexander Fred Markham, David Mark Meredith
  • Herpesvirus saimiri as viral vector
    Patent number: 6379967
    Abstract: The invention relates to herpesvirus saimiri viruses that are genetically modified by mutations and/or deleting specific essential and non-essential genes. The essential genes are required in replication of viral genes and are needed for viral proliferation. The non-essential genes can represent sites for the insertion of heterologous genetic material.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: April 30, 2002
    Assignee: The University of Leeds
    Inventors: David Mark Meredith, Alexander Fred Markham
  • Detection of APC proteins
    Patent number: 6114124
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 5, 2000
    Assignees: The Johns Hopkins University, University of Utah, The Cancer Institute, Imperial Chemical Industries PLC
    Inventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
  • DNA encoding ubiquitin conjugating enzymes
    Patent number: 5952481
    Abstract: The invention relates to methods for determining a predisposition for and diagnosing the existence of a degenerative disease or a cancer and also products and processes for treating and obtaining treatments for such a degenerative disease or a cancer. The invention has particular application in the use of information concerning the elucidation of DNA and amino acid sequence structure relating to human and mouse ubiquitin conjugating enzymes.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: September 14, 1999
    Assignee: The University of Leeds
    Inventors: Alexander Fred Markham, Philip Alan Robinson
  • Yeast artificial chromosomes containing DNA encoding the cystic fibrosis (CFTR) gene
    Patent number: 5939255
    Abstract: Yeast Artificial Chromosomes (YACS) containing DNA encoding the cystic fibrosis (CFTR) gene are described. The YACs allow detailed analysis of the coding and non-coding regions of the gene and the determination of cystic fibrosis alleles in sample DNA from an individual or individuals.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: August 17, 1999
    Assignee: Zeneca Limited
    Inventors: Rakesh Anand, Alexander Fred Markham, John Craig Smith, Rashida Anwar, John Hamilton Riley, Donald James Ogilvie, Paul Elvin
  • APC (adenomatous polyosis coli) protein
    Patent number: 5783666
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 21, 1998
    Assignees: The Johns Hopkins University, The University of Utah, Zeneca Pharmaceuticals, The Cancer Institute
    Inventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
  • APC antibodies
    Patent number: 5691454
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: November 25, 1997
    Assignees: The Johns Hopkins University, University of Utah, the Cancer Institute, Imperial Chemical Industries PLC
    Inventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
  • APC Antibodies
    Patent number: RE38916
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: December 6, 2005
    Assignees: The Johns Hopkins University, The University of Utah, The Cancer Institute, Zeneca Limited
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuka Nakamura, Andrew Thilveris, Raymond L. White
  • APC antibodies
    Patent number: RE40948
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: October 27, 2009
    Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of Utah
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White
  • APC gene and nucleic acid probes derived therefrom
    Patent number: RE36713
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in hum tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as wel as in sporadic colorectal cancer patents. APC is expressed in most normal tissue. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: May 23, 2000
    Assignees: The Johns Hopkins University, The University of Utah, Zeneca, Cancer Institute
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertson, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Raymond White